Tragic Toll: Toxic Cough Syrup Crisis Threatens Indian Pharma

A probe into toxic cough syrup in India reveals at least 14 child deaths due to contaminated Coldrif Syrup. The incident damages India's pharmaceutical reputation amidst emerging details of unsafe diethylene glycol levels. Authorities face pressure as ties to previous international poisonings highlight systemic safety challenges.

Indian authorities have launched a manslaughter investigation following the deaths of at least 14 children linked to toxic cough syrup, Coldrif Syrup, highlighting ongoing safety issues in the country's pharmaceutical industry.

The syrup, containing dangerous levels of diethylene glycol, reportedly caused kidney failure in young children under five. This incident follows previous cases of cough syrup poisonings involving the same toxin in Gambia, Uzbekistan, and Cameroon.

The implicated manufacturer, Sresan Pharma, is facing charges, while heightened scrutiny targets India's drug manufacturing practices amid concerns over safety regulations for both domestic and international markets.